The stock ended with a decline of Rs 35.40 or 2.05% over the Tuesday closing price.
There will also be an oversubscription option of 5.3 million shares or 3.4% of equity, the report said. The total stake sale could be as much as 10.2% or 10.6 million, including oversubscription option.
The transaction value is estimated at Rs 1,717.4 crore ($200 million) for the 6.8% holding, the report said.
The Book Running Lead Managers (BRLMs) are Kotak Securities, Jefferies, IIFL Capital, Spark (adviser).
The value of greenshoe to retain oversubscription is Rs 861 crore or $100 million.JB Chemicals is a pharmaceutical company which boasts of varied products and dosage forms across therapeutic categories. It offers products related to gastroenterology, hypertension, and dermatology and has also entered newer therapeutic categories like nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy (NRT).Shares of JB Chemicals have followed a losing trend in 2025 so far, declining by nearly 10%. Its one-year returns stand at 5%.
The stock is currently trading below its 200-day simple moving average of Rs 1,801 while managing to remain above its 50-day SMA of Rs 1,669.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
